Skip to content

Study of MIRUSâ?¢ Disposable Hemorrhoids Stapler used in surgery during the treatment of prolapsed Hemorrhoids (Piles) to evaluate safety and efficacy of the device in post marketing period.

A prospective, open-label, single-arm, multicenter, post marketing surveillance study to evaluate safety and performance of MIRUSâ?¢ Disposable Hemorrhoids Stapler in the treatment of prolapsed Hemorrhoids. - MIRUSâ?¢ Disposable Hemorrhoids Stapler

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
CTRI
Registry ID
CTRI/2017/05/008476
Enrollment
80
Registered
2017-05-03
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: MIRUSâ?¢ Disposable Hemorrhoids Stapler: MIRUSâ?¢ Disposable Hemorrhoids Stapler in the treatment of prolapsed hemorrhoids. Control Intervention1: NA: NA

Sponsors

Meril Endo Surgery Pvt Ltd
Lead Sponsor
Meril Life Science Pvt Ltd
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Each potential subject must satisfy all of the following criteria to be enrolled in the study: 1. Male and female subjects who are 18 to 80 years of age. 2. Those subjects with late grade II hemorrhoids and unlikely to respond to one or two sessions of rubber band ligation (RBL) and/or conservative treatment. OR 3. Subjects with grade III (prolapsing internal hemorrhoids requiring manual reduction) and/or grade IV (irreducible prolapse) are suitable candidate with stapled hemorrhoidopexy. 4. Subject must sign an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study. 5. Subject must follow the post-operative follow-up visits for 6 months.

Exclusion criteria

Exclusion criteria: Any potential subject who meets any of the following criteria will be excluded from participating in the study: 1. Any female subject, who is pregnant, suspected pregnancy at the time of screening. 2. Subjectâ??s tissue thickness found to be less than 0.75mm or greater then 1.5mm, or where the internal diameter of the rectum will not be able to accommodate the instrument and accessories. 3. Subjectâ??s tissue has undergone multiple injections of hardening agent at hemorrhoids. 4. The subject has a history of fecal incontinence. 5. The subject has an active or a history of infection requiring antibiotics at the intended operative site within 30 days prior to the planned surgery date. 6. The subject has a history of venous thrombosis or pulmonary embolism. 7. The subject has a history of coagulopathy. 8. The subject has taken aspirin, anti coagulation and/or anti platelet therapies (e.g. Warfarin, Lovenox) within 7 days prior to the planned date of surgery. 9. The subject has existing anal stenosis/severe mucosal edema or any other co-morbidities which in the opinion of the investigator will not be appropriate for the study. 10. Subject undergone multiple injections in tissue, using hardening agents or with history of acutely prolapsed thrombosed piles associated anal fistulas (abnormal connection between anal canal & skin), anal fissures (anal ulcer), abscess (pus under the skin surrounding the anus) or rectal prolapse.

Design outcomes

Primary

MeasureTime frame
- Immediate postoperative complications and short term outcomes related to study device. - Number of AE/SAE related to study device during 6 month of study period. - Post Operative PainTimepoint: At baseline, Post-procedure,15 days (±7 days), 3 months (±28 days) and 6 months (±28 days)

Secondary

MeasureTime frame
1. Incidence of Stapler Malfunction or Misfires 2. Operation Time 3. Length of Hospital Stay 4. Reapparition of the hemorroidal symptoms and/or Reoperations 5. Standardized Stapled Hemmorrhoidectomy Quality Of Life (QOL) 6. Overall Quality of LifeTimepoint: At baseline, About 20 minutes for procedure, Day 0, time of discharge minus time of admission , 15 days (±7 days), 3 months (±28 days) and 6 months (±28 days)

Countries

India

Contacts

Public ContactDr Ashok Thakkar

Meril Life Science Pvt Ltd

ashok.thakkar@merillife.com9879443584

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026